<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
</table>
| **FEV-5/FEV-A**  
External request:  
Submission from Melinta Therapeutics (10/1/18) to include meropenem and vaborbactam as a therapeutic option for the treatment of serious infections by: (1) adding meropenem and vaborbactam to the FEV-5 Initial Empiric Therapy for Fever and Neutropenia; IV Antibiotic Therapy; and (2) adding meropenem and vaborbactam to the FEV-A Antibacterial Agents: Anti-Pseudomonal Agents table. | Based on a review of the data and discussion, the panel consensus did not support the addition of these specific recommendations into the Guidelines. | 0 | 19 | 0 | 6 |
| **FEV-5**  
Internal request:  
Comment to consider the inclusion of IV vancomycin for patients with anaphylactic allergic reaction to penicillins.  
Internal request:  
Comment to consider the inclusion of IV aztreonam for patients with anaphylactic allergic reaction to penicillins. | Based on the discussion, the panel consensus was to include IV vancomycin as an option for patients with anaphylactic allergic reaction to penicillins. This is a category 2A recommendation. | 19 | 0 | 0 | 6 |
| | Based on the discussion, the panel consensus was to include IV aztreonam as an option for patients with anaphylactic allergic reaction to penicillins. This is a category 2A recommendation. | 19 | 0 | 0 | 6 |